|
skos:definition |
MSH: An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.,NCI: An anticancer drug that belongs to the family of drugs called antitumor antibiotics.,PDQ: A semisynthetic anthracycline antineoplastic antibiotic derived from daunorubicin. Idarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes better than other anthracycline antibiotics. Idarubicin hydrochloride is the therapeutic form of this drug. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39753&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39753&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C56
|
